Company Information
Products
Technical Literature
Application Notes
Bibliography
Published PDFs
Request More Information
Hemodyne News
Investor Information
Technical Support
Contact Us
Home
1. Thrombotic Risk
A. Risk Assessment
i. Elevated PCF in Diabetics
ii. Buergers Disease
B. Drug Monitoring
i. PCF and Glycoprotein
ii. Reversal of Heparin
iii. PCF and Non-heparin
2. Bleeding Risk
i. Prediction of Blood Loss
ii. PCF in Glanzmann's
iii. Decreased PCF in Renal
i. Dose Dependent Effects of NovoSeven
Hemodyne, Inc. 3126 W. Cary St.#445 Richmond, VA 23221-2905 Email: requestinfo@hemodyne.com For Research Use Only in the US